NEW YORK – On the heels of a 510(k) clearance from the US Food and Drug Administration for its point-of-care diabetes diagnostic test, Abbott is embarking on a longer-term strategy to drive greater adoption of HbA1c testing.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.